MOONLAKE IMMUNOTHERAPEUTICS Other Comprehensive Income (Loss), Net of Tax
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Other Comprehensive Income (Loss), Net of Tax of $308.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was $308.00K.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$282.00K.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $322.00K, a 85.37% decline year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$247.00K.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive income (loss), net of tax for fiscal 2025 was -$4.48M, a 272.45% decline from fiscal 2024.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive income (loss), net of tax for fiscal 2024 was $2.60M, a 30.34% increase from fiscal 2023.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive income (loss), net of tax for fiscal 2023 was $1.99M, a 201.83% increase from fiscal 2022.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive income (loss), net of tax for fiscal 2022 was $660.65K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 6 month as first filed | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 9 month as first filed | Other Comprehensive Income (Loss), Net of Tax 10 month | Other Comprehensive Income (Loss), Net of Tax 12 month | Other Comprehensive Income (Loss), Net of Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $308.00K 10-Q · filed 2026-08-10 | $26.00K 10-Q · filed 2026-08-10 | $348.00K derived: sum of 3 quarters · filed 2026-08-10 | $101.00K derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2026-03-31 | -$282.00K 10-Q · filed 2026-05-11 | $40.00K derived: sum of 2 quarters · filed 2026-05-11 | -$207.00K derived: sum of 3 quarters · filed 2026-05-11 | -$2.10M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-12-31 | $322.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $75.00K derived: sum of 2 quarters · filed 2026-02-25 | -$1.82M derived: sum of 3 quarters · filed 2026-08-10 | -$4.48M 10-K · filed 2026-02-25 | |||||
| 2025-09-30 | -$247.00K 10-Q · filed 2025-11-05 | -$2.14M derived: sum of 2 quarters · filed 2026-08-10 | -$4.80M 10-Q · filed 2025-11-05 | -$2.60M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-06-30 | -$1.90M 10-Q · filed 2026-08-10 | -$4.56M 10-Q · filed 2026-08-10 | -$2.35M derived: sum of 3 quarters · filed 2026-08-10 | -$2.80M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-03-31 | -$2.66M 10-Q · filed 2026-08-10 | -$460.00K derived: sum of 2 quarters · filed 2026-08-10 | -$901.00K derived: sum of 3 quarters · filed 2026-08-10 | -$325.00K derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2024-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.76M derived: sum of 2 quarters · filed 2026-02-25 | $2.34M derived: sum of 3 quarters · filed 2026-02-25 | $2.60M 10-K · filed 2026-02-25 | $2.60M 10-K · filed 2025-02-26 | ||||
| 2024-09-30 | -$441.00K 10-Q · filed 2025-11-05 | -$441.14K 10-Q · filed 2024-11-07 | $135.00K derived: sum of 2 quarters · filed 2025-11-05 | $398.00K 10-Q · filed 2025-11-05 | $397.98K 10-Q · filed 2024-11-07 | -$635.22K derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | $576.00K 10-Q · filed 2025-11-05 | $575.62K 10-Q · filed 2024-08-07 | $839.00K 10-Q · filed 2025-08-05 | $839.12K 10-Q · filed 2024-08-07 | -$194.22K derived: sum of 3 quarters · filed 2026-02-25 | $3.28M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | $263.00K 10-Q · filed 2025-11-05 | $263.50K 10-Q · filed 2024-05-07 | -$770.22K derived: sum of 2 quarters · filed 2026-02-25 | $2.71M derived: sum of 3 quarters · filed 2026-02-25 | $2.27M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.44M derived: sum of 2 quarters · filed 2026-02-25 | $2.01M derived: sum of 3 quarters · filed 2026-02-25 | $1.99M 10-K · filed 2026-02-25 | $1.99M 10-K · filed 2024-02-29 | ||||
| 2023-09-30 | $3.48M 10-Q · filed 2024-11-07 | $3.04M derived: sum of 2 quarters · filed 2024-11-07 | $3.03M 10-Q · filed 2024-11-07 | $3.15M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2023-06-30 | -$431.56K 10-Q · filed 2024-11-07 | -$449.23K 10-Q · filed 2024-08-07 | -$323.04K derived: sum of 3 quarters · filed 2025-02-26 | -$156.45K derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2023-03-31 | -$17.67K 10-Q · filed 2024-11-07 | $108.52K derived: sum of 2 quarters · filed 2025-02-26 | $275.11K derived: sum of 3 quarters · filed 2025-02-26 | $376.71K derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2022-12-31 | $126.19K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $292.78K derived: sum of 2 quarters · filed 2025-02-26 | $394.38K derived: sum of 3 quarters · filed 2025-02-26 | $660.65K 10-K · filed 2025-02-26 | |||||
| 2022-09-30 | $166.59K 10-Q · filed 2023-11-14 | $268.19K derived: sum of 2 quarters · filed 2023-11-14 | $534.46K 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | $101.60K 10-Q · filed 2023-11-14 | $367.87K 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | $266.27K 10-Q · filed 2023-11-14 | ||||||||
| 2021-12-31 | -$168.18K 10-K · filed 2023-03-20 | ||||||||
| 2021-09-30 | $1.00K 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$1.00K 10-Q · filed 2022-11-14 | -$1.00K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |